Healthy
Conditions
Keywords
INTERCEPT, Platelet, Pathogen Inactivation, Platelets Components Stored, Therapeutic Efficacy
Brief summary
The objective of this study is to test the hypothesis that INTERCEPT Blood System for platelet components stored for 6 or 7 days after INTERCEPT Blood System treatment retain sufficient viability for therapeutic efficacy. The post-infusion recovery and lifespan of autologous INTERCEPT Blood System for platelet components in 35% plasma/65% InterSol (Test platelets) stored for 6 or 7 days will be measured in comparison to fresh autologous radiolabeled platelets (Control platelets) according to FDA guidance for platelet testing (FDA 1999). Recovery and lifespan results between components stored for 6 and 7 days will also be assessed.
Detailed description
For each of the 2 study donation periods, this study will have the following procedures: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT Blood System treatment, storage for 6 or 7 days (depending on the period and randomization scheme) at 20°C to 24°C with agitation, collection of fresh autologous platelets, radiolabeling, infusion of fresh and stored INTERCEPT Blood System-treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). There will be a minimum wash-out period of two weeks between the two study periods. Apheresis platelets will be collected using the Amicus separator and stored for 6 or 7 days (depending on the period and randomization scheme) in 35% plasma/65% InterSol. Procedures will be as follows: On Day 0, each healthy volunteer subject has apheresis platelets collected. INTERCEPT Blood System treatment will begin on either the day of donation (Day 0) or the day following donation (Day 1) and will be completed within 24 hours after collection. Platelets will then be stored for 6 or 7 days after collection (depending on the period and randomization scheme) at 22°C ±2°C with agitation. Aliquots for in vitro platelet function will be taken on Day 0/1 before INTERCEPT Blood System treatment and on Day 6 or 7. On Day 6 or 7, healthy volunteers will return to the site, and 43 mL of blood will be drawn into a syringe containing 9 mL of Anticoagulant Citrate Dextrose Solution, Formula A (ACD-A). Fresh platelets will be prepared from this sample. An aliquot (10-20 mL) of the stored INTERCEPT Blood System for platelets will be aseptically removed from each subject's test container. Previously stored (Test) and fresh (Control) platelets will be radiolabeled according to randomization assignment with either Chromium-51 (51Cr) (≤20 μCi) as sodium radiochromate (Na251CrO4) or Indium-111 (111In) (≤15 μCi) as indium oxine, following the labeling and washing procedures outlined by the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. The isotope labels will be assigned randomly with equal probability that fresh platelets and stored INTERCEPT Blood System for platelets will be labeled with each isotope., and the same randomization assignment of isotope labels will be utilized for both donation periods for the same subject. Aliquots of the fresh and stored platelets will be radiolabeled in tubes with the standard techniques. After radiolabeling, the autologous fresh and stored INTERCEPT Blood System for platelets will be simultaneously infused into the subject (approximately 10-30 mL). Negative pregnancy test for females of childbearing potential are required before infusion. Blood samples for radioactivity measurements will be drawn immediately before infusion and at approximately 0, 0.5, 1, and 2 hours post-infusion, and then 6 more samples will be drawn at 1, 2, 3, 4 (or 6), 7, and 11±1 days post-infusion, at approximately the same time of day as the radiolabeled platelet infusion was administered (±4 hours). Patients will be monitored for safety (adverse events) from the beginning of the study until 10 days following the infusion of radiolabelled platelets in period 2. Radioactivity measurements Samples will be obtained from the radiolabeled fresh and stored INTERCEPT Blood System for platelets before infusion and used as a radioactive standard. By measuring the volume infused, the total dose of radioactivity infused will be calculated. In vitro elution of the label from the transfused platelets will be determined by the BEST elution assessment method, as well as the in vivo elution of radioactivity from the serial blood samples obtained post-infusion of the labeled platelets. The standard as well as the subject's whole-blood samples will be corrected for elution and also for the residual activity in the cellular fraction one day after the infusion. Data points 24 hours post-infusion will be used to calculate in vivo recovery after all radioactive corrections have been made. The radioactivity of the samples will be determined by use of a gamma counter. A multiple-hit model will be used to estimate the survival of the radioactively labeled platelets.
Interventions
BIOLOGICALAutologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.
Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
BIOLOGICALAutologous apheresis Conventional untreated Platelet Components
Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
Sponsors
Cerus Corporation
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Normal health status (as determined by the Investigator review of medical history and blood donor physical exam) * Meet FDA, American Association of Blood Banks (AABB), and site guidelines for blood donation or apheresis platelet donation * Complete blood count (CBC) and serum chemistry values within established reference ranges or within guidelines as above. * Pre-donation platelet count of more than 150×10\^9 platelets/L * Negative blood donor screening test panel for Human Immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-Lymphotropic virus (HTLV), syphilis, and West Nile virus (WNV) * Male and female subjects of childbearing potential must agree to use a medically acceptable method of contraception throughout the study. A barrier method of contraception must be included, regardless of other methods. * Signed and dated informed consent form
Exclusion criteria
* Clinically significant acute or chronic disease (as determined by the Investigator) * Pregnant or nursing females * Male or female subjects of childbearing potential not using effective contraception * Disease states or conditions that preclude blood donation or apheresis platelet donation per AABB reference standards * Treatment with aspirin or aspirin-containing medications within 7 days of apheresis or treatment with non-steroidal anti inflammatory drugs (NSAID), anti-platelet agents or other drugs affecting platelet viability within 3 days of apheresis (e.g. ibuprofen or other NSAIDs) * Subject received platelet inhibitor within 14 days of donation (e.g. clopidogrel, ticlopidine) * Splenectomized subjects * History of known hypersensitivity to indium or chromium * Participation in another clinical study currently or within the past 28 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post infusion lifespan of the platelets at Day 6 platelets compared to Day 7 platelets. | 16 Days |
| Blood Urea Nitrogen (mg/dL) | 16 Days |
| Calcium (mg/dL) | 16 Days |
| Chloride (mEq/L) | 16 Days |
| Creatinine (mg/dL) | 16 Days |
| Glucose (mg/dL) | 16 Days |
| Potassium (mEq/L) | 16 Days |
| Sodium (mEq/L) | 16 Days |
| Post infusion recovery of the Test platelets compared to fresh platelets. | 16 Days |
| Post infusion lifespan of Test platelets compared to fresh platelets. | 16 Days |
| Adverse events: any untold medical occurrence in a subject or clinical investigation subject administered an investigational product and which does not necessarily have a causal relationship with this treatment. | 16 Days |
| Body Mass Index (kg/m^2) | 16 Days |
| Hematocrit (g/dL) | 16 Days |
| Hemoglobin (g/dL) | 16 Days |
| Red Blood Cell Count (x10^12/L) | 16 Days |
| Platelet Count (×10^3μL) | 16 Days |
| Post infusion recovery of the platelets at Day 6 platelets compared to Day 7 platelets. | 16 Days |
| White Blood Cell Count - with Differential (x10^9/L) | 16 Days |
Secondary
| Measure | Time frame |
|---|---|
| Platelet count (×10^3/μL) | 16 Days |
| Platelet dose (×10^11 cells/component) | 16 Days |
| Mean platelet volume (MPV) (fL) | 16 Days |
| Morphology score (Kunicki Score) | 16 Days |
| Component volume (mL) | 16 Days |
| Glucose (mmol/L) | 16 Days |
| Lactate (mmol/L) | 16 Days |
| pO2 (mm Hg) | 16 Days |
| pCO2 (mm Hg) | 16 Days |
| Bicarbonate (HCO3-) (mmol/L) | 16 Days |
| Lactate dehydrogenase (IU/L) | 16 Days |
| Hypotonic Shock Response (HSR) (%) | 16 Days |
| Extent of Shape Change (ESC) (%) | 16 Days |
| p-selectin expression (CD62) (% activation) | 16 Days |
| Adenosine 5'-Triphosphate (ATP) (nmol/10^8 platelets) | 16 Days |
| pH (pH) | 16 Days |
Countries
United States
Outcome results
None listed